-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Movement disorders in Parkinson's disease (PD) are often characterized by tremors, postural instability, and decreased gait speed
Movement disorders in Parkinson's disease (PD) are often characterized by tremors, postural instability, and decreased gait speed
Figure 1 Title map of the paper
Figure 1 Title map of the paperTherefore, treatment of Parkinson's disease focuses on the use of dopamine compensation (primarily levodopa) and surgical approaches (such as deep brain stimulation) to control motor and non-motor symptoms
Therefore, treatment of Parkinson's disease focuses on the use of dopamine compensation (primarily levodopa) and surgical approaches (such as deep brain stimulation) to control motor and non-motor symptoms
Based on IMU signals or derived gait parameters, one can classify early PD, study subtle differences between PD patients, predict freezing of gait, monitor PD symptoms, and levodopa responses during long-term daily activities
Among various gait parameters, gait speed is often considered the sixth vital sign and has been shown to be a reliable measure in diagnosis and a marker of functional decline
Being wearable, the IMU allows assessment of gait in both clinical and home settings
For example, studies have shown that during daily activities, gait speed in PD patients can be reduced by 30% compared to the clinic
Furthermore, the environment at home or outdoors is different, where there are multiple obstacles and is more complex compared to the clinical environment
They found that, on average, patients had similar patterns in the clinic and in their daily activities
In addition, the number of doses taken throughout the day was somewhat correlated with differences between clinics and households
In addition, the number of doses taken throughout the day was somewhat correlated with differences between clinics and households
Overall, only about 3 percent had a gait speed equal to or greater than the patient's ability in the clinic
Gait measurement can better assist in the control of drug intake in PD because it takes into account both functional capacity and continuous monitoring of gait speed under real-life conditions
Original source:
Atrsaei A, Corrà MF, Dadashi F, et al.
Gait speed in clinical and daily living assessments in Parkinson's disease patients: performance versus capacity.
npj Parkinsons Dis.
2021;7(1):24.
doi:10.
1038/s41531 -021-00171-0 Gait speed in clinical and daily living assessments in Parkinson's disease patients: performance versus capacity.
Leave a comment here